Marinus Pharmaceuticals (MRNS) R&D Day Provides Update on Ganaxolone’s Clinical Trials, PT to $9 at H.C. Wainwright
Tweet Send to a Friend
H.C. Wainwright analyst Douglas Tsao reiterated a Buy rating on Marinus Pharmaceuticals (NASDAQ: MRNS) and raised the price target to ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
